Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug safety
Biotech
Syndax stock slips after AML drug hits midstage trial goal
The treatment’s overall response rate was 47% in the phase 2 portion of the trial, down from 63% in the phase 1 part.
Darren Incorvaia
Nov 12, 2024 2:00pm
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Oct 29, 2024 6:16am
Karuna's schizophrenia drug clears blood pressure test
Nov 17, 2023 8:52am
Astellas finds underlying liver issues in gene therapy deaths
Nov 16, 2023 7:12am
Innate lymphoma trials put on partial hold after patient dies
Oct 5, 2023 6:20am
Merck KGaA grows Quris toxicity AI pact, continuing deal flurry
Sep 28, 2023 10:10am
